The One Big Beautiful Bill Act and the future of prostate cancer care

The One Big Beautiful Bill Act (OBBBA), signed into law in July 2025, introduced sweeping changes to Medicaid financing. Although framed as measures intended to foster independence and fiscal sustainability, these policies risk destabilizing continuity of care for cancer patients. Prostate cancer patients represent a sizeable population that may be impacted by the OBBBA, as prostate cancer is the most commonly diagnosed cancer in men in the United States. Patients with favorable-risk prostate cancer who are managed through active surveillance may in particular be at risk of poor oncologic outcomes due to restructured health care financing. Active surveillance-an evidence-based strategy for managing early-stage prostate cancer-relies on regular monitoring with imaging, laboratory testing, and biopsies. Temporary insurance gaps or modest increases in out-of-pocket costs could disrupt adherence to surveillance schedules, resulting in delayed detection of cancer progression, avoidable overtreatment, or late-stage presentation. Sustainable Medicaid reform is essential, but policies that undermine evidence-based management can heighten disparities, increase long-term costs, and compromise survival in prostate cancer care. Without careful recalibration, the OBBBA risks widening disparities and reversing decades of progress in management of favorable-risk prostate cancer.